TradingKey

Más Datos de Charles River Laboratories International Inc Compañía

Charles River Laboratories International, Inc. is a drug development company. It provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions around the globe accelerate their research and drug development efforts. Its Research Models and Services segment includes three businesses that provide foundational tools that enable its clients to discover new molecules: Research Models, Research Model Services, and Cell Solutions. Its Discovery and Safety Assessment segment provides regulated and non-regulated DSA services to support the research, development, and regulatory-required safety testing of potential new drugs, including therapeutic discovery and optimization plus in vitro and in vivo studies, laboratory support services, and strategic non-clinical consulting and program management to support product development. Its Manufacturing Solutions segment includes Microbial Solutions and Biologics Solutions.

Información de la empresa

Símbolo de cotizaciónCRL

Nombre de la empresaCharles River Laboratories International Inc

Fecha de salida a bolsaJun 23, 2000

Fundada en1994

Director ejecutivoMr James C. Foster

Número de empleados18600

Tipo de seguridadOrdinary Share

Fin del año fiscalJun 23

Dirección251 Ballardvale St

CiudadWILMINGTON

Bolsa de valoresNYSE Consolidated

PaísUnited States of America

Código postal01887

Teléfono17812226000

Sitio Webhttps://www.criver.com/

Símbolo de cotizaciónCRL

Fecha de salida a bolsaJun 23, 2000

Fundada en1994

Ejecutivos de la empresa

Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Mr James C. Foster

Chairman of the Board, President, Chief Executive Officer

267.96K

+6.88%

Ms. Birgit Girshick

Chief Operating Officer, Corporate Executive Vice President

57.72K

+24.38%

Ms. Victoria L. (Vicky) Creamer

Corporate Executive Vice President, Chief People Officer

17.89K

+48.67%

Mr. Joseph W. LaPlume

Corporate Executive Vice President - Corporate Development and Strategy

13.68K

-2.74%

Ms. Shannon M. Parisotto

Corporate Executive Vice President - Discovery and Safety Assessment Management

12.88K

+69.56%

Ms. Virginia M. (Gina) Wilson, CPA

Independent Director

4.91K

+23.86%

Dr. Nancy C. Andrews, M.D., Ph.D.

Independent Director

3.96K

+31.35%

Ms. Reshema Kemps-Polanco

Independent Director

2.59K

+155.42%

Dr. Craig B. Thompson, M.D.

Independent Director

2.41K

+64.49%

Mr. Abraham N. (Abe) Ceesay

Independent Director

946.00

--

Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Mr James C. Foster

Chairman of the Board, President, Chief Executive Officer

267.96K

+6.88%

Ms. Birgit Girshick

Chief Operating Officer, Corporate Executive Vice President

57.72K

+24.38%

Ms. Victoria L. (Vicky) Creamer

Corporate Executive Vice President, Chief People Officer

17.89K

+48.67%

Mr. Joseph W. LaPlume

Corporate Executive Vice President - Corporate Development and Strategy

13.68K

-2.74%

Ms. Shannon M. Parisotto

Corporate Executive Vice President - Discovery and Safety Assessment Management

12.88K

+69.56%

Ms. Virginia M. (Gina) Wilson, CPA

Independent Director

4.91K

+23.86%

Desglose de ingresos

Divisa: USDActualizado: dom., 6 de jul

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

FY2017

FY2016

FY2015

Por negocioUSD

Nombre

Ganancia

Proporción

DSA

592.61M

60.21%

RMS

213.07M

21.65%

Manufacturing

178.49M

18.14%

Por regiónUSD

Nombre

Ganancia

Proporción

United States

536.96M

54.56%

Europe

263.25M

26.75%

Canada

125.35M

12.74%

Asia Pacific (Region)

41.94M

4.26%

Other

16.67M

1.69%

Por negocio

Por región

Por negocioUSD

Nombre

Ganancia

Proporción

DSA

592.61M

60.21%

RMS

213.07M

21.65%

Manufacturing

178.49M

18.14%

Estadísticas de accionistas

Actualizado: sáb., 17 de may

Accionistas

Tipos de accionistas

Accionistas

Proporción

The Vanguard Group, Inc.

12.41%

Wellington Management Company, LLP

8.72%

BlackRock Institutional Trust Company, N.A.

5.92%

UBS Financial Services, Inc.

4.86%

Allspring Global Investments, LLC

4.66%

Other

63.42%

Accionistas

Proporción

The Vanguard Group, Inc.

12.41%

Wellington Management Company, LLP

8.72%

BlackRock Institutional Trust Company, N.A.

5.92%

UBS Financial Services, Inc.

4.86%

Allspring Global Investments, LLC

4.66%

Other

63.42%

Tipos de accionistas

Accionistas

Proporción

Investment Advisor

51.51%

Investment Advisor/Hedge Fund

40.20%

Hedge Fund

7.75%

Research Firm

7.62%

Pension Fund

1.84%

Bank and Trust

1.48%

Sovereign Wealth Fund

1.10%

Individual Investor

1.05%

Insurance Company

0.08%

Participación institucional

Actualizado: mar., 1 de jul

Periodo del informe

Número de instituciones

Acciones mantenidas

Proporción

Cambio

2025Q2

1392

55.35M

112.69%

-5.40M

2025Q1

1435

55.38M

112.72%

-5.93M

2024Q4

1423

54.85M

107.26%

-4.35M

2024Q3

1392

53.78M

105.14%

-5.12M

2024Q2

1399

54.00M

104.84%

-4.00M

2024Q1

1393

53.76M

104.37%

-4.04M

2023Q4

1424

53.56M

104.42%

-4.24M

2023Q3

1446

53.56M

104.42%

-3.98M

2023Q2

1427

52.88M

103.32%

-3.95M

2023Q1

1431

52.72M

103.01%

-2.79M

Actividad de los accionistas

Nombre

Acciones mantenidas

Proporción

Cambio

Cambio %

Fecha

The Vanguard Group, Inc.

6.09M

12.41%

-39.84K

-0.65%

Mar 31, 2025

Wellington Management Company, LLP

4.29M

8.72%

+208.59K

+5.12%

Mar 31, 2025

BlackRock Institutional Trust Company, N.A.

2.91M

5.92%

-42.75K

-1.45%

Mar 31, 2025

UBS Financial Services, Inc.

2.39M

4.86%

+2.09M

+702.65%

Mar 31, 2025

Allspring Global Investments, LLC

1.77M

3.61%

-33.40K

-1.85%

Mar 31, 2025

Kayne Anderson Rudnick Investment Management, LLC

1.95M

3.97%

+144.73K

+8.02%

Mar 31, 2025

State Street Global Advisors (US)

1.90M

3.87%

-278.81K

-12.78%

Mar 31, 2025

Geode Capital Management, L.L.C.

1.26M

2.57%

+30.45K

+2.47%

Mar 31, 2025

Impactive Capital LP

1.21M

2.47%

+9.20K

+0.77%

Mar 31, 2025

Ariel Investments, LLC

1.10M

2.24%

+33.45K

+3.13%

Mar 31, 2025

ETFs relacionados

Actualizado: hace 4 horas

Nombre

Proporción

First Trust NASDAQ Pharmaceuticals ETF

2.12%

Invesco S&P 500 Equal Weight Health Care ETF

1.66%

VanEck Biotech ETF

1.62%

ROBO Global Healthcare Technology & Innovation ETF

1.55%

Schwab Ariel Opportunities ETF

1.48%

Franklin Genomic Advancements ETF

1.38%

iShares Health Innovation Active ETF

1.27%

WisdomTree US Value Fund

0.96%

Principal Quality ETF

0.9%

Pacer CFRA-Stovall Equal Weight Seasonal Rot Idx

0.84%

First Trust NASDAQ Pharmaceuticals ETF

Proporción2.12%

Invesco S&P 500 Equal Weight Health Care ETF

Proporción1.66%

VanEck Biotech ETF

Proporción1.62%

ROBO Global Healthcare Technology & Innovation ETF

Proporción1.55%

Schwab Ariel Opportunities ETF

Proporción1.48%

Franklin Genomic Advancements ETF

Proporción1.38%

iShares Health Innovation Active ETF

Proporción1.27%

WisdomTree US Value Fund

Proporción0.96%

Principal Quality ETF

Proporción0.9%

Pacer CFRA-Stovall Equal Weight Seasonal Rot Idx

Proporción0.84%

Dividendos

Un total de 0.00 USD se ha distribuido en dividendos durante los últimos 5 años.

Fecha

Dividendos

Fecha de registro

Fecha de pago

Fecha ex-dividendo

Sin datos

División de acciones

Fecha

Tipo

Relación

Sin datos

Fecha

Tipo

Relación

Sin datos

Charles River Laboratories International Inc

166.910USD

Charles River Laboratories International Inc

166.910

Descripción general

Compañía

Finanzas